ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;

APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN

OFFICERS.

Appointment of President and Chief Executive Officer

On January 5, 2022, Zymeworks Inc. (the "Company") announced via press release that the Company's board of directors (the "Board") appointed Mr. Kenneth Galbraith, age 59, as President, Chief Executive Officer and Chair of the Board of the Company, effective upon his commencement of employment with the Company, which is anticipated to be on or before February 1, 2022 (the "Start Date"). In connection with Mr. Galbraith's appointment, Dr. Ali Tehrani resigned from the positions of President and Chief Executive Officer and as a member of the Board, effective as of the Start Date. The Board also appointed Ms. Lota Zoth, the current Chair of the Board, as the Board's lead independent director, effective as of the Start Date.

Mr. Galbraith is a Managing Director at Five Corners Capital, Inc., which he founded in 2013, and has served as Executive in Residence at Syncona Limited since April 2021. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of MacroGenics, Inc. since July 2008 and as a director of Profound Medical Corp. since January 2017, both of which are publicly held companies. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 30 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Based on Mr. Galbraith's depth of experience in the biotechnology industry, ranging from executive officer to director roles, the Board believes Mr. Galbraith has the appropriate set of skills to serve as a member of our Board.

There are no arrangements or understandings between Mr. Galbraith and any other persons pursuant to which he was appointed President, Chief Executive Officer and Chair of the Board. There are also no family relationships between Mr. Galbraith and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with Mr. Galbraith's appointment as President and Chief Executive Officer, the Company and Mr. Galbraith entered into an employment agreement (the "Galbraith Employment Agreement"). The Galbraith Employment Agreement does not have a specific term.

Pursuant to the Galbraith Employment Agreement, Mr. Galbraith is entitled to the following compensation and benefits:





  •   An annual base salary of $600,000, with eligibility to earn an annual
      discretionary bonus of up to 60% of his annual base salary, based upon the
      achievement of certain Company goals determined by the Board.




  •   Options to purchase 500,000 of the Company's common shares at an exercise
      price per share equal to the fair market value on the date of grant (the
      "Inducement Options"). 25% of the Inducement Options will vest and become
      exercisable on the one-year anniversary of the date of grant, and thereafter
      1/36 of the remaining Inducement Options will vest on the last day of each
      month, until all of the Inducement Options have vested, subject to
      Mr. Galbraith's continued service. The Inducement Options will be granted as
      an "inducement" grant pursuant to the New York Stock Exchange ("NYSE") Listed
      Company Manual Rule 303A.08 and without shareholder approval. The Inducement
      Option grant will be made under the recently adopted Zymeworks Inc.
      Inducement Stock Option and Equity Compensation Plan, further described
      below. The terms and conditions of the Inducement Options are substantially
      similar to options granted pursuant to the Company's Amended and Restated
      Stock Option and Equity Compensation Plan (the "Equity Compensation Plan"),
      but with such other terms and conditions intended to comply with the NYSE
      inducement award exception. In accordance with NYSE Listed Company Manual
      Rule 303A.08, inducement awards may only be made as a material inducement to
      individuals being hired by the Company (or being rehired after a bona fide
      period of interruption of employment). A copy of the form of inducement
      option grant agreement is attached as a schedule to the Inducement Plan (as
      defined below), which is attached hereto as Exhibit 10.4 and incorporated by
      reference herein.




  •   Eligibility to participate in the Company's employee benefit plans, policies
      and arrangements that, in the aggregate, are reasonably consistent with other
      executive officers generally.




  •   Enrollment in a qualifying pension scheme under the UK Pensions Act 2008.




  •   Reimbursement of relocation expenses up to a maximum gross amount of
      $300,000, grossed up for the impact of any taxable withholding, for
      reasonable moving expenses incurred by Mr. Galbraith and his immediate family
      during relocation from Mr. Galbraith's primary residence to the Vancouver,
      British Columbia or Seattle, Washington area during the first eighteen months
      of employment. The total amount reimbursed shall be repaid to the Company if
      Mr. Galbraith's employment terminates within two years following the
      effective date of employment.




                                       2

--------------------------------------------------------------------------------

• Temporary housing through the earlier of Mr. Galbraith's relocation or the


      date that is 18 months following the effective date of employment, grossed up
      for the impact of any tax withholding.



• A tax equalization payment if Mr. Galbraith is subject to income taxation or


      other taxation outside of the United Kingdom during the period of his
      employment, grossed up for the impact of any tax withholding, and tax
      preparation services.



• If the Company terminates Mr. Galbraith's employment, then Mr. Galbraith will


      be eligible to receive twelve months of notice or the equivalent of twelve
      months of base salary as of the date notice is given, or any combination
      thereof that totals twelve months of combined notice and base salary. If such
      termination of employment or resignation occurs on or after the fourth year
      of employment, Mr. Galbraith will be eligible to receive an additional one
      month of notice or the equivalent of one month of base salary as of the date
      notice is given, or any combination thereof, for each additional completed
      year of service, up to a total maximum of eighteen months. Mr. Galbraith will
      also be eligible for continuation of group health and dental benefits through
      the applicable notice period to the extent permitted by any applicable
      benefit plan.



• In the event of termination on death or disability, as defined in the


      Company's long-term disability plan or policy then in effect with respect to
      him, Mr. Galbraith, or his estate, will receive (x) a lump sum payment equal
      to the difference between (1) eighteen months of base salary plus target
      annual cash bonus as of the date of death or disability and (2) the amount
      that Mr. Galbraith or his estate will receive as a result of death or
      disability under the Company's applicable insurance policies in effect as of
      the date of termination, (y) group extended health and dental benefits
      continuation for his surviving family members for eighteen months (or lump
      sum payment for the premium costs of such benefits in lieu thereof), and
      (z) full vesting acceleration of all unvested and outstanding stock options
      or other equity grants made to Mr. Galbraith as of the date of death or
      disability.



• If Mr. Galbraith's employment is terminated by the Company without cause


      within twelve months following, or within three months prior to, a Change of
      Control (as defined in the Galbraith Employment Agreement), Mr. Galbraith
      will be eligible to receive (x) a lump sum payment of eighteen months of base
      salary and 100% of target annual cash bonus as of the date of termination,
      (y) group extended health and dental benefits continuation as of the date of
      termination for eighteen months (or lump sum payment for the premium costs of
      such benefit plans in lieu thereof) and (z) full vesting acceleration of all
      unvested and outstanding stock options or other equity grants as of the date
      of termination. Such payments will be subject to Mr. Galbraith entering into
      a valid settlement agreement with the Company.



• In addition, the Galbraith Employment Agreement requires Mr. Galbraith, among

other things, not to compete, either directly or indirectly, with the Company

while employed by the Company and for up to six months following the

termination of his employment with the Company. The Galbraith Employment

Agreement also requires Mr. Galbraith not to solicit the Company's employees . . .




ITEM 8.01 OTHER EVENTS.


On January 5, 2022, the Company filed a material change report with Canadian securities regulators regarding the appointment of Mr. Galbraith as Chair, President and Chief Executive Officer of the Company. A copy of this material change report is attached as Exhibit 99.2 hereto.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS




(d) Exhibits



Exhibit No.       Description

10.1                Employment Agreement by and between the Company and Kenneth
                  Galbraith, dated January 5, 2022.

10.2                Separation Agreement and Release by and between the Company and
                  Ali Tehrani, dated January 5, 2022.

10.3                Promotion Letter from the Company to Neil Klompas, dated
                  January 5, 2022.

10.4                Zymeworks Inc. Inducement Stock Option and Equity Compensation
                  Plan.

99.1                Press Release dated January 5, 2022.

99.2                Material Change Report dated January 5, 2022.

104               Cover Page Interactive Data File (embedded as Inline XBRL
                  document).




                                       5

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses